17-Beta-estradiol induces neoplastic transformation in prostatic epithelial cells

Cancer Letters

Volumn 304, Issue 1, 2011, Pages 8-20

  Yu, Shan ^a   Zhang, Yan ^a   Yuen, Mong Ting ^a   Zou, Chang ^a   Danielpour, David ^b   Chan, Franky L ^a  

^a Chinese University of Hong Kong   (Hong Kong)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Estrogen carcinogenicity; Immortalization; Prostate cancer; Prostatic epithelial cell; Transformation

Indexed keywords

ANDROGEN RECEPTOR; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HERMES ANTIGEN; MATRIGEL; VERY LATE ACTIVATION ANTIGEN 2;

AGAR MEDIUM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL CULTURE; CELL GROWTH; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; EPITHELIUM CELL; GENOTOXICITY; IN VITRO STUDY; MALE; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MUS MUSCULUS; RATTUS;

EID: 79952242102     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.003     Document Type: Article

References (57)

1. Mawhinney M.G., Belis J.A. Androgens and estrogens in prostatic neoplasia. Adv. Sex Horm. Res. 1976, 2:141-209.
2. Bosland M.C. The role of steroid hormones in prostate carcinogenesis. J. Natl. Cancer Inst. Monogr. 2000, 27:39-66.
3. Ho S.M. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell. Biochem. 2004, 91:491-503.
4. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J. Cell. Biochem. 2007, 102:899-911.
5. Prezioso D., Denis L.J., Klocker H., Sciarra A., Reis M., Naber K., Lobel B., Pacik D., Griffiths K. Estrogens and aspects of prostate disease. Int. J. Urol. 2007, 14:1-16.
6. Singh P.B., Matanhelia S.S., Martin F.L. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur. J. Cancer 2008, 44:928-936.
7. Malkowicz S.B. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001, 58(Suppl. 2A):108-113.
8. Daskivich T.J., Oh W.K. Recent progress in hormonal therapy for advanced prostate cancer. Curr. Opin. Urol. 2006, 16:173-178.
9. Leav I., Lau K.M., Adams J.Y., McNeal J.E., Taplin M.E., Wang J., Singh H., Ho S.M. Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 2001, 159:79-92.
10. Prins G.S., Korach K.S. The role of estrogens and estrogens receptors in normal prostate growth and disease. Steroid 2008, 73:233-244.
11. Bonkhoff H., Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur. Urol. 2009, 55:533-542.
12. Matskin H., Soloway M.S. Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues. Prostate 1992, 21:309-314.
13. Hiramatsu M., Maehara I., Ozaki M., Harada N., Orikasa S., Sasano H. Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 1997, 31:118-124.
14. Ellem S.J., Schmitt J.F., Pedersen J.S., Frydenberg M., Risbridger G.P. Local aromatase expression in human prostate is altered in malignancy. J. Clin. Endocrinol. Metab. 2004, 89:2434-2441.
15. Ellem S.J., Risbridger G.S. Aromatase and regulating the estrogen: androgen ratio in the prostate gland. J. Steroid Biochem. Mol. Biol. 2010, 118:246-251.
16. Härkönen P., Törn S., Kurkela R., Porvari K., Pulkka A., Lindfors A., Isomaa V., Vihko P. Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state. J. Clin. Endocrinol. Metab. 2003, 88:705-712.
17. Soronen P., Laiti M., Törn S., Härkönen P., Patrikainen L., Li Y., Pulkka A., Kurkela R., Herrala A., Kaija H., Isomaa V., Vihko P. Sex steroid hormone metabolism and prostate cancer. J. Steroid Biochem. Mol. Biol. 2004, 92:281-286.
18. Takase Y., Lévesque M.H., Luu-The V., El-Alfy M., Labrie F., Pelletier G. Expression of enzymes involved in estrogen metabolism in human prostate. J. Histochem. Cytochem. 2006, 54:911-921.
19. Mawhinney M.G., Neubauer B.L. Actions of estrogen in the male. Invest. Urol. 1979, 16:409-420.
20. Vermeulen A., Andropause Maturitas 2000, 34:5-15.
21. Harman S.M., Metter E.J., Tobin J.D., Pearson J., Blackman M.R. Longitudinal effects of aging on serum total and free testosterone levels in health men. J. Clin. Endocrinol. Metab. 2001, 86:724-731.
22. Hsing A.W. Hormones and prostate cancer: what's next?. Epidermiol. Rev. 2001, 23:42-58.
23. Hill P., Wynder E.L., Garbaczewski L., Walker A.R.P. Effect of diet on plasma and urinary hormones in South African black men with prostatic cancer. Cancer Res. 1982, 42:3864-3869.
24. Kozák I., Bartsch W., Krieg M., Voigt K.D. Nuclei of stroma: site of highest estrogen concentration in human benign prostatic hyperplasia. Prostate 1982, 3:433-438.
25. Krieg M., Nass R., Tunn S. Effect of aging on endogenous level of 5α-dihydrotestosterone testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J. Clin. Endocrinol. Metab. 1993, 77:375-381.
26. Ahluwalia B., Jackson M.A., Jones G.W., Williams A.O., Rao M.S., Rajguru S. Blood hormone profiles in prostate cancer patients in high-risk and low-risk populations. Cancer 1981, 48:2267-2273.
27. Henderson B.E., Bernstein L., Ross R.K., Depue R.H., Judd H.L. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br. J. Cancer 1988, 57:216-218.
28. Muti P., Westerlind K., Wu T., Grimaldi T., De Berry J., Schünemann H., Freudenheim J.L., Hill H., Carruba G., Bradlow L. Urinary estrogen metabolites and prostate cancer: a case-control study in the United States. Cancer Causes Control 2002, 13:947-955.
29. Yang L., Gailwad N.W., Meza J., Cavalieri E.L., Muti P., Trock B., Rogan E.G. Novel biomarkers for risk of prostate cancer: results from a case-control study. Prostate 2009, 69:41-48.
30. Tanaka Y., Sasaki M., Shiina H., Tokizane T., Deguchi M., Hirata H., Hinoda Y., Okayama N., Suehiro Y., Urakami S., Kawakami T., Kaneuchi M., Pookot D., Igawa M., Okuyama A., Ishii N., Dahiya R. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer. Cancer Epidermiol. Biomarkers Prev. 2006, 15:238-244.
31. Nock N.L., Cicek M.S., Li L., Liu X., Rybicki B.A., Moreira A., Plummer S.J., Casey G., Witte J.S. Polymorphisms in estrogen inactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 2006, 27:1842-1848.
32. Cussenot O., Azzouzi A.R., Nicolaiew N., Fromont G., Mangin P., Cormier L., Fournier G., Valeri A., Larre S., Thibault F., Giodanella J.P., Pouchard M., Zheng Y., Hamdy F.C., Cox A., Cancel-Tassin G. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J. Clin. Oncol. 2007, 25:3596-3602.
33. Cavalieri E., Chakravarti D., Guttenplan J., Hart E., Ingle J., Jankowiak R., Muti P., Rogan E., Russo J., Santen R., Sutter T. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim. Biophys. Acta 2006, 1766:63-78.
34. Mueller A., Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur. J. Endocrinol. 2008, 159:197-202.
35. Noble R.L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res. 1977, 37:1929-1933.
36. Leav I., Ho S.M., Ofner P., Merk F.B., Kwan P.W., Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J. Natl. Cancer Inst. 1988, 80:1045-1053.
37. Bosland M.C., Ford H., Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. Carcinogenesis 1995, 16:1311-1317.
38. Yuen M.T., Leung L.K., Wang J., Wong Y.C., Chan F.L. Enhanced induction of prostatic dysplasia and carcinoma in Noble rat model by combination of neonatal estrogen exposure and hormonal treatments at adulthood. Int. J. Oncol. 2005, 27:1685-1695.
39. Santti R., Newbold R.R., Mäkelä S., Pylkkänen L., McLachlan J.A. Developmental estrogenization and prostatic neoplasia. Prostate 1994, 24:67-78.
40. Prins G.S., Birch L., Tang W.Y., Ho S.M. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod. Toxicol. 2007, 23:374-382.
41. Setlur S.R., Mertz K.D., Hoshida Y., Demichelis F., Lupien M., Perner S., Sboner A., Pawitan Y., Andrén O., Johnson L.A., Tang J., Adami H.O., Calza S., Chinnaiyan A.M., Rhodes D., Tomlins S., Fall K., Mucci L.A., Kantoff P.W., Stampfer M.J., Andersson S.O., Varenhorst E., Johansson J.E., Brown M., Golub T.R., Rubin M.A. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J. Natl. Cancer Inst. 2008, 100:815-825.
42. Danielpour D., Kadomatsu K., Anzano M.A., Smith J.M., Sporn M.B. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res. 1994, 54:3413-3421.
43. Chu J.H., Yu S., Hayward S.W., Chan F.L. Development of a three-dimensional culture method of prostatic epithelial cells and its use for the study of epithelial-mesenchymal transition and inhibition of PI3K pathway in prostate cancer. Prostate 2009, 69:428-442.
44. Li H., Chen X., Calhoun-Davis T., Claypool K., Tang D.G. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res. 2008, 68:1820-1825.
45. Wang Y., Sudilovsky D., Zhang B., Haughney P.C., Rosen M.A., Wu D.S., Cunha T.J., Dahiya R., Cunha G.R., Hayward S.W. A human prostatic epithelial model of hormonal carcinogenesis. Cancer Res. 2001, 61:6064-6072.
46. Hayward S.W., Wang Y., Cao M., Hom Y.K., Zhang B., Grossfeld G.D., Sudilovsky D., Cunha G.R. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 2001, 61:8135-8142.
47. Carruba G., Pfeffer U., Fecarotta E., Coviello D.A., D'Amato E., Lo Casto M.L., Vidali G., Castagnetta L. Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. Cancer Res. 1994, 54:1190-1193.
48. Robertson C.N., Roberson K.M., Padilla G.M., O'Brien E.T., Cook J.M., Kim C.S., Fine R.L. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J. Natl. Cancer. Inst. 1996, 88:908-917.
49. Corey E., Quinn J.E., Emond M.J., Buhler K.R., Brown L.G., Vessella R.L. Inhibition of androgen-independent growth of prostate cancer xenografts by 17β-estradiol. Clin. Cancer Res. 2002, 8:1003-1007.
50. Qiao Y., Zhang Z.K., Cai L.Q., Tan C., Imperato-McGinley J.L., Zhu Y.S. 17α-Estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals. Prostate 2007, 67:1719-1728.
51. Russo J., Hu Y.F., Tahin Q., Mihaila D., Slater C., Lareef M.H., Russo I.H. Carcinogenicity of estrogens in human breast epithelial cells. APMIS 2001, 109:39-52.
52. Russo J., Lareef M.H., Balogh G., Guo S., Russo I.H. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J. Steroid Biochem. Mol. Biol. 2003, 87:1-25.
53. Saeed M., Rogan E., Fernandez S.V., Sheriff F., Russo J., Cavalieri E. Formation of depurinating N3Adenine and N7Guanine adducts by MCF-10F cells cultured in the presence of 4-hydroxyestradiol. Int. J. Cancer 2007, 120:1821-1824.
54. Cheng A.S.L., Culhane A.C., Chan M.W.Y., Venkataramu C.R., Ehrich M., Nasir A., Rodriguez B.A.T., Liu J., Yan P.S., Quackenbush J., Nephew K.P., Yeatman T.J., Huang T.H. Epithelial progeny of estrogen-exposure breast progenitor cells display a cancer-like methylome. Cancer Res. 2008, 68:1786-1796.
55. Ward R.J., Dirks P.B. Cancer stem cells: at the headwaters of tumor development. Annu. Rev. Pathol. 2007, 2:175-189.
56. Maitland N.J., Collins A.T. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 2008, 26:2862-2870.
57. Danielpour D. Transdifferentiation of NRP-152 rat prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-beta. J. Cell Sci. 1999, 112:169-179.